Park Ji Soo, Chon Hong Jae, Jeung Hei-Cheul, Shin Sang Joon, Rha Sun Young, Ahn Joong Bae, Lee Kang Young, Kim Nam Kyu, Chung Hyun Cheol
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea.
Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
J Cancer Res Clin Oncol. 2016 Sep;142(9):2051-9. doi: 10.1007/s00432-016-2208-2. Epub 2016 Jul 22.
We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy.
We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS).
The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348-4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241-4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130-2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035-0.517; p = 0.003).
We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.
我们研究了韩国II期结肠癌患者复发的预后因素,并评估了基于5-氟尿嘧啶(FU)的辅助化疗对其的预测意义。
我们分析了716例行根治性切除的II期结肠癌患者的临床病理特征与无复发生存期(RFS)之间的关系。使用5年RFS和5年癌症特异性生存率(CSS)评估预测价值。
5年RFS、5年CSS、5年无病生存率和5年总生存率分别为87.4%、94.9%、84.8%和90.5%。多因素Cox回归分析显示,T4期(风险比[HR],2.342;95%置信区间[CI],1.348 - 4.068;p = 0.003)、术前肠梗阻或穿孔(HR 2.428;95% CI 1.241 - 4.752;p = 0.010)以及年龄大于70岁(HR 1.740;95% CI 1.130 - 2.678;p = 0.012)是复发的不良预后因素。在60例T4期疾病患者中,基于5-FU的辅助化疗使患者5年CSS得到改善(90.3%对46.7%;HR 0.135;95% CI 0.035 - 0.517;p = 0.003)。
我们发现韩国II期结肠癌患者复发的危险因素与基于5-FU的辅助化疗的预测价值之间存在不一致。未来需要针对高危患者进行选择性的前瞻性临床试验。